SkinHealth Systems COO Sheri Lewis to Resign

SkinHealth Systems Inc. reported that Sheri Lewis has decided to resign from her role as Chief Operations, Quality and Technology Officer to pursue other business opportunities outside the company.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

SkinHealth Systems Inc. reported that Sheri Lewis has decided to resign from her role as Chief Operations, Quality and Technology Officer to pursue other business opportunities outside the company. She notified the company on August 10, 2026, and will step down effective August 28, 2026.

The company states that Ms. Lewis’ resignation is not due to any disagreement with SkinHealth Systems, its board of directors, or management regarding operations, policies, or practices.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Key Figures

Notice date of resignation: August 10, 2026 Effective resignation date: August 28, 2026

2 metrics

Notice date of resignation August 10, 2026 Date Sheri Lewis notified the company of her decision to resign

Effective resignation date August 28, 2026 Date Sheri Lewis will cease serving as Chief Operations, Quality and Technology Officer

Key Terms

Emerging growth company, Chief Operations, Quality and Technology Officer, Exchange Act

3 terms

Emerging growth company regulatory

"Emerging growth company Item 5.02."

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

Chief Operations, Quality and Technology Officer financial

"resign as its Chief Operations, Quality and Technology Officer"

Exchange Act regulatory

"Securities Exchange Act of 1934"

A federal law that sets rules for trading securities on public exchanges, requiring companies and market participants to register, disclose regular financial information, and follow standards that promote honest, orderly markets. For investors, it matters because it creates transparency and legal protections—like stopping insider trading and ensuring timely company disclosures—so you can evaluate risks and rely on consistent rules much as players rely on a referee to keep a game fair.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What leadership change did SkinHealth Systems (SKIN) disclose on August 10, 2026?

SkinHealth Systems disclosed that Sheri Lewis decided to resign as Chief Operations, Quality and Technology Officer. She informed the company on August 10, 2026, and will leave effective August 28, 2026, to pursue other business opportunities.

When is Sheri Lewis’s resignation from SkinHealth Systems (SKIN) effective?

Sheri Lewis’s resignation from SkinHealth Systems is effective August 28, 2026. She will cease serving as Chief Operations, Quality and Technology Officer on that date, following her notice to the company on August 10, 2026.

Did Sheri Lewis resign from SkinHealth Systems (SKIN) due to a disagreement with management?

No, Sheri Lewis’s resignation is stated not to result from any disagreement with SkinHealth Systems, its board of directors, or management on operations, policies, or practices. The company characterizes her departure as a decision to pursue other opportunities.

What position did Sheri Lewis hold at SkinHealth Systems (SKIN) before her resignation?

Before her resignation, Sheri Lewis served as Chief Operations, Quality and Technology Officer at SkinHealth Systems. The company describes her role as covering operations, quality, and technology functions until her planned departure on August 28, 2026.

What reason did SkinHealth Systems (SKIN) give for Sheri Lewis’s departure?

SkinHealth Systems reports that Sheri Lewis resigned to pursue other business opportunities outside the company. It also states that her resignation is not due to any disagreement on the company’s operations, policies, or practices with management or the board.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 08/14/2026 - 04:12 PM Accepted by SEC EDGAR 08/14/2026 - 04:05 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 10, 2026

SkinHealth Systems Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-39565

85-1908962

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

3600 E. Burnett Street

Long Beach, CA

(Address of principal executive offices)

90815

(Zip Code)

(800) 603-4996

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange

on which registered

Class A Common Stock, par value $0.0001 per share

SKIN

The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Chief Operating Officer Departure

On August 10, 2026, Sheri Lewis notified SkinHealth Systems Inc. (the “Company”) of her decision to resign as its Chief Operations, Quality and Technology Officer to pursue other business opportunities outside of the Company. Effective August 28, 2026, Ms. Lewis will cease serving as the Company's Chief Operations, Quality and Technology Officer.

Ms. Lewis’ resignation is not the result of any disagreement with the Company, its Board of Directors, or Management on any matter relating to the Company's operations, policies, or practices.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Dated: August 14, 2026	SkinHealth Systems Inc.

	By:	/s/ Michael Monahan
	Name:	Michael Monahan
	Title:	Chief Financial Officer

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

4 documents